FTTP

FTTP is a chimeric peptide with a prohibitin-targeting “homing” domain and a pro-apoptotic domain. It binds vasculature of white adipose tissue, disrupting blood supply to adipocytes and inducing apoptosis, leading to targeted fat loss and improved metabolic parameters.

- Seek targeted fat loss (e.g., abdominal)

- Aim to reduce visceral fat and improve metabolic health

Mechanism of Action

How this peptide works in the body

Targeted Binding to Adipose Vasculature: ● FTTP contains a homing sequence that specifically binds to prohibitin, a receptor abundantly expressed on the surface of endothelial cells in WAT vasculature. This selective binding ensures targeted delivery of the pro-apoptotic domain to adipose tissue. Induction of Apoptosis in Vascular Endothelial Cells: ● The pro-apoptotic domain of FTTP mimics the activity of BH3-only proteins, initiating the intrinsic apoptotic pathway.This leads to mitochondrial outer membrane permeabilization, cytochrome c release, and activation of caspases, culminating in endothelial cell apoptosis. Disruption of Adipose Tissue Blood Supply: ● Apoptosis of endothelial cells results in the collapse of the microvasculature within WAT, effectively starving adipocytes of oxygen and nutrients. This ischemic environment triggers secondary apoptosis of adipocytes. Reduction of Adipose Tissue Mass: ● The combined loss of vascular and adipocyte cells leads to a significant reduction in WAT mass. This effect is particularly pronounced in visceral fat depots, which are closely linked to metabolic diseases. Improvement in Metabolic Parameters: ● The reduction in visceral fat mass is associated with improved insulin sensitivity, decreased circulating free fatty acids, and enhanced glucose tolerance, contributing to overall metabolic health.